Matinas BioPharma to Webcast Q1 2024 Financial Results and Business Update on May 9, 2024

BEDMINSTER, N.J., May 02, 2024 – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company, has announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market closes. The company's management will conduct a conference call and webcast to discuss these results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Interested participants can join the call by dialing 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will also be accessible on the Matinas website's IR Calendar page and will be archived for six months.

Matinas BioPharma specializes in developing innovative therapies using its lipid nanocrystal (LNC) platform delivery technology. The company's primary LNC-based therapy is MAT2203, an oral formulation of amphotericin B, a potent broad-spectrum antifungal medication. Amphotericin B is typically known for its significant toxicity when administered intravenously. However, Matinas' LNC platform allows for oral delivery of the drug, significantly reducing the nephrotoxicity that is usually associated with its intravenous forms. This approach combines effective fungicidal activity with targeted delivery, mitigating the risk of toxicity and potentially creating an optimal antifungal treatment for invasive fungal infections.

MAT2203 has shown promising results in clinical trials. Specifically, the Phase 2 EnACT study in HIV patients with cryptococcal meningitis met its primary endpoint and demonstrated strong survival rates. MAT2203 is slated for further evaluation in a single Phase 3 registration trial called the "ORALTO" trial. In this trial, it will be used as an oral step-down monotherapy following treatment with AmBisome® (liposomal amphotericin B), in comparison to the standard care for patients with invasive aspergillosis who have limited treatment options.

Beyond MAT2203, preclinical and clinical data indicate that Matinas' LNC technology could offer solutions to several challenges associated with safely and effectively delivering both small molecules and larger, more complex molecular cargos intracellularly. This includes small oligonucleotides such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA). Due to its unique mechanism of action and versatility in administration routes, including oral administration, the LNC technology is well-positioned to become a preferred platform for next-generation oral intracellular drug delivery.

Matinas BioPharma remains committed to advancing its LNC technology and exploring its potential applications in various therapeutic areas. The company continues to look for opportunities to develop, license, and partner with other entities to further its product candidates and delivery technologies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!